ertugliflozin sold brand name steglatro medication treatment type common side effects include fungal infections vagina infections female reproductive ertugliflozin sodiumglucose cotransporter class drugs known united states approved food drug administration use monotherapy fixed dose combination either sitagliptin european union approved march use monotherapy combination september new england journal medicine reported ertugliflozin shown essentially noninferior placebo respect cardiovascular combination metformin marketed segluromet combination sitagliptin marketed steglatro indicated treatment adults insufficiently controlled type diabetes adjunct diet exercise monotherapy metformin considered inappropriate due intolerance contraindications addition medicinal products treatment us approval ertugliflozin contraindicated patients severe kidney failure endstage renal disease european union approval list contraindications apart hypersensitivity drug standard drug adverse effects studies significantly common ertugliflozin placebo included mycosis genitals men women vaginal itch increased urination thirst hypoglycaemia low blood sugar weight loss higher dosing scheme rare lifethreatening side effect gliflozins ketoacidosis occurred three patients ertugliflozin lessen risk developing ketoacidosis serious condition body produces high levels blood acids called ketones surgery fda approved changes prescribing information inhibitor diabetes medicines recommend stopped temporarily scheduled surgery ertugliflozin stopped least four days scheduled symptoms ketoacidosis include nausea vomiting abdominal pain tiredness trouble sixfold clinical doses two weeks single doses tolerated patients without toxic many diabetes drugs combining ertugliflozin insulin insulin secretagogues sulfonylureas may result increased risk low blood sugar combination diuretics may result higher risk dehydration low blood pressure clinically relevant pharmacokinetic interactions found oral intake ertugliflozin practically completely absorbed gut undergoes relevant firstpass effect highest blood plasma concentrations reached one hour circulation substance bound plasma proteins ertugliflocin metabolised mainly glucuronides enzymes cytochrome enzymes play minor role elimination halflife estimated hours eliminated via feces unchanged form metabolites via urine unchanged metabolites high proportion unchanged substance feces probably due hydrolysis metabolites back parent ertugliflozin ertugliflozinmetformin ertugliflozinsitagliptin approved medical use united states december european union march httpsenwikipediaorgwikiertugliflozin